Mon, November 16, 2009
Sun, November 15, 2009
Fri, November 13, 2009
Thu, November 12, 2009
Wed, November 11, 2009
Tue, November 10, 2009
Mon, November 9, 2009
Fri, November 6, 2009
Thu, November 5, 2009
Wed, November 4, 2009

TSO3 announces financial results for Q3 2009 and updates on negotiations with 3M

[ CNW Group ]
[ Home | ][ Products & Services ] | [ Social Media Releases ] | [ About Us ] | [ Contact Us ][ Client Login ] | [ Français ]

TSO3 INC.

[ TSO3 INC. ]

[ ] >[ TELL A FRIEND ] >[ PRINTER FRIENDLY ] >[ SUBSCRIBE TO PORTFOLIO E-MAIL ]

[ Save to del.icio.us ] [ Submit to Digg ] [ Seed Newsvine ] [ Find blogs discussing this release ]

TSO3 INC.
[ Detailed Chart... ]
TSO3 INC.
[ Detailed Chart... ]

TSO3 announces financial results for Q3 2009 and updates on negotiations with 3M

 Stock symbol: TSX: TOS Outstanding shares: 47,863,402 Highlights of Q3 2009 and recent weeks: - Progressed in due diligence and negotiations with 3M toward signing a channel partner agreement within the agreed upon 90 day period; - Completed new cycle development and initiated data collection to support filings with regulatory agencies in Canada, United States and Europe; - Filed patent applications to extend protection for new cycles; - John H. Stroger Hospital of Cook County announced in press release adoption of STERIZONE(R) technology. Benefits cited include cost- effective and eco-friendliness; - Continued interaction with US regulatory agency supporting request for expanded claims of sterile efficacy for multi-channel flexible endoscopes. 
 SUMMARY OF OPERATING RESULTS Periods ended September 30, 2009 (Unaudited) ------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------- THIRD QUARTER NINE MONTHS ------------- ----------- ------------------------------------------------------------------------- 2009 2008 2009 2008 ------------------------------------------------------------------------- SALES $ 126,162 $ 725,257 $1,170,276 $1,853,584 ------------------------------------------------------------------------- EXPENSES ------------------------------------------------------------------------- Operating 359,275 704,574 1,530,267 1,864,636 ------------------------------------------------------------------------- Sales & Marketing 524,748 724,311 1,780,369 2,919,073 ------------------------------------------------------------------------- Research & Development 876,118 634,390 2,390,273 1,870,407 ------------------------------------------------------------------------- Administrative 718,322 708,284 2,240,998 2,626,534 ------------------------------------------------------------------------- Financial 6,488 6,092 16,387 18,309 ------------------------------------------------------------------------- 2,484,951 2,777,651 7,958,294 9,298,959 ------------------------------------------------------------------------- ------------------------------------------------------------------------- OPERATING LOSS 2,358,789 2,052,394 6,788,018 7,445,375 ------------------------------------------------------------------------- Other Revenues 71,078 203,535 249,500 708,952 ------------------------------------------------------------------------- NET LOSS AND COMPREHENSIVE LOSS $2,287,711 $1,848,859 $6,538,518 $6,736,423 ------------------------------------------------------------------------- BASIC AND DILUTED NET LOSS PER SHARE $ 0.05 $ 0.04 $ 0.14 $ 0.14 ------------------------------------------------------------------------- WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING 47,863,402 47,863,402 47,863,402 47,863,402 ------------------------------------------------------------------------- ------------------------------------------------------------------------- OPERATING RESULTS ANALYSIS ------------------------------------------------------------------------- ------------------------------------------------------------------------- 
 The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.